Nuclear magnetic resonance (NMR) imaging is an emerging diagnostic tool capable of providing clinically-useful images without the use of ionizing radiation. Contrast enhancing drugs, used in conjunction with NMR imaging, have been shown to supplement the information yield from images by better localizing and characterizing normal and diseased tissues. The development of NMR contrast agents is in an early stage; NMR contrast agents have been shown to be effective and useful in experimental studies, but no agent has yet met criteria of safety and efficacy for clinical use in humans. The principle aim of this continuing research program is to further test the safety, diagnostic benefits, and pharmacology of nitroxide spin labels (NSL), a group of synthetic, paramagnetic, organic molecules, applies as in vivo contrast agents for NMR imaging.
Specific aims i nclude 1) to select and synthesize candidate nonionic and polyradical NSL pharmaceuticals with superior properties of tolerance, relaxivity, and inertness, 2) to conduct extensive toxicological evaluatios of super-selected NSL's in preparation for clinical trails, 3) to continue NSL metabolic studies, including the definition of cellular and extracellular bioreduction pathways, to better apply NSL as extracellular space contrast enhancers and to identify candidate NSL's to be tested as redox-sensitive, metabolic contrast agents, 4) to synthesize and test potentially function-specific NSL contrast agents and 5) to assess the diagnostic efficacy of using NSL for image contrast enhancement in normal and diseased (tumor, inflammatory, ischemic) experimental animals. The proposed investigations require a combination of disciplines including diagnostic imaging, synthetic and analytical chemistry, NMR physics, and pharmacology. Specific techniques to be emphasized will be pulsed nuclear magnetic resonance (NMR), electron paramagnetic resonane (EPR), NMR imaging, and radiotracer detection. Experimental models of neoplastic, inflammatory, and vascular disases and obstructive uropathy will be studied by NMR before and after NSL administration to assess the diagnostic utility of contrast enhancement. The long-term goal is to develop clinically useful NMR contrast agents for use in the diagnosis of human disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
2R01DK031937-04
Application #
3230430
Study Section
Diagnostic Radiology Study Section (RNM)
Project Start
1983-02-01
Project End
1989-06-30
Budget Start
1986-07-01
Budget End
1987-06-30
Support Year
4
Fiscal Year
1986
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Wikstrom, M (1992) MR imaging of experimental myocardial infarction. Acta Radiol Suppl 379:1-30
Moseley, M E; Chew, W M; White, D L et al. (1992) Hypercarbia-induced changes in cerebral blood volume in the cat: a 1H MRI and intravascular contrast agent study. Magn Reson Med 23:21-30
Aicher, K P; Dupon, J W; White, D L et al. (1990) Contrast-enhanced magnetic resonance imaging of tumor-bearing mice treated with human recombinant tumor necrosis factor alpha. Cancer Res 50:7376-81
Brasch, R C; Moseley, M E; Dupon, J et al. (1990) Macromolecular magnetic resonance imaging contrast media. Accumulated experience. Invest Radiol 25 Suppl 1:S51-2
Wang, S C; Wikstrom, M G; White, D L et al. (1990) Evaluation of Gd-DTPA-labeled dextran as an intravascular MR contrast agent: imaging characteristics in normal rat tissues. Radiology 175:483-8
Wikstrom, M G; Moseley, M E; White, D L et al. (1989) Contrast-enhanced MRI of tumors. Comparison of Gd-DTPA and a macromolecular agent. Invest Radiol 24:609-15
Moseley, M E; White, D L; Wang, S C et al. (1989) Vascular mapping using albumin-(Gd-DTPA), an intravascular MR contrast agent, and projection MR imaging. J Comput Assist Tomogr 13:215-21
Wikstrom, M G; White, D L; Moseley, M E et al. (1989) Ascorbate-induced cancellation of nitroxide contrast media enhancement of MR images. Invest Radiol 24:692-6
Schmiedl, U; Sievers, R E; Brasch, R C et al. (1989) Acute myocardial ischemia and reperfusion: MR imaging with albumin-Gd-DTPA. Radiology 170:351-6
Tien, R D; Brasch, R C; Jackson, D E et al. (1989) Cerebral Erdheim-Chester disease: persistent enhancement with Gd-DTPA on MR images. Radiology 172:791-2

Showing the most recent 10 out of 11 publications